Age, active surveillance, and age-related risk for progression

A new report in the Journal of Clinical Oncology suggests that younger patients had a somewhat lower risk for biopsy-based Gleason score upgrade while on active surveillance (AS) than older patients. … READ MORE …

This may be good news … or it may not …

Barvarian Nordic has again delayed (slightly) when they expect to have the initial results of the Phase III clinical trial of Prostvac in the treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Genetics, genomics, targeted therapy, and the costs of care

A new paper in a new journal argues that all men diagnosed with advanced forms of prostate cancer should now, routinely, be undergoing tumor and germline DNA profiling … READ MORE …

Unnecessary imaging studies … it’s on the docs!

Here in the USA, about half the patients diagnosed with low-risk prostate cancer are still (apparently) being sent for “guideline-discordant” (i.e., unnecessary) bone scans and CT scans, … READ MORE …

This isn’t nice … it isn’t “fair” … but it’s true … and it’s important …

According to an article from Kaiser Health News on the CNN web site today, “People with advanced cancer don’t know enough about their disease to make informed decisions about treatment or how they want to spend their remaining time.” … READ MORE …

Why do African Americans do better on Provenge than whites?

In general, being of African American race is not a good thing when it comes to prostate cancer-related risk (for getting diagnosed with the disease or for outcomes over time). However, … … READ MORE …

At ASCO this year … “one that got away”

An abstract that we missed at the ASCO meeting this year came to our attention when we read this article by Dr. Jeffrey Kirshner: “Ten practice changes I will make after attending ASCO 2017“. … READ MORE …